Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
SARS-CoV-2: early-phase trial registry
5 of 35 indexed SARS-CoV-2 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #435 of 28,707 conditions by registered trial count.
35 US clinical trials · 5 currently recruiting · #435 of 28,707 conditions by registered trial count
SARS-CoV-2: 35 US clinical trials tracked, 5 recruiting.
SARS-CoV-2 is the subject of 35 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is ModernaTX, running 5 of these trials.
Enrollment posture brief
Registry condition sars-cov-2
OPEN 5 | RECR 14% | LATE 7 | EARLY 11 | RANK #435 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Adverse Drug Events (14% recruiting · 7 trials)
SARS-CoV-2 lists 5 open slots (14% of 35 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for SARS-CoV-2 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
SARS-CoV-2 is recruiting below its size-band peers.
5 of 35 indexed trials (14.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of SARS-CoV-2 trials is spread across many organizations.
ModernaTX accounts for 5 of 35 trials (14.3%). 29 distinct sponsors appear on at least one study for this condition label.
-
Typical SARS-CoV-2 enrolment sits around 245 participants.
Median target enrolment is 245 among the 35 trials that report a genuine target (sentinel values excluded). 9 of those (25.7%) plan for fewer than 100 participants.
-
SARS-CoV-2 splits between interventional and observational designs.
24 interventional and 11 observational studies make up this index (68.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
35 total, page 1 of 1
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
ModernaTX
NCT07266558
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
ModernaTX
NCT06585241
Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence
Columbia University
NCT04448145
Improving the Collaborative Health of Minority COVID-19 Survivor and Carepartner Dyads
University of South Carolina
NCT05370014
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
Stephanie B. Seminara, MD
NCT07224490
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
Vaxart
NCT06672055
COVID-19 Biorepository
University of Kansas Medical Center
NCT04568148
Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia
Ohio State University Comprehensive Cancer Center
NCT04466683
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
Pfizer
NCT05876377
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
AstraZeneca
NCT04516746
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
ModernaTX
NCT04470427
Epidemiology, Immunology and Clinical Characteristics of COVID-19 (EPIC3)
VA Office of Research and Development
NCT05764083
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
ModernaTX
NCT05827926
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications
Johns Hopkins University
NCT04373460
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff
Eli Lilly and Company
NCT04497987
Network-Targeted Strategies for Efficient Community SARS-CoV-2 (COVID-19) Sampling
Duke University
NCT04437706
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
University of Minnesota
NCT04546581
Monitoring Serologic Response to Severe Acute Respiratory Syndrome-2 (SARS-COV-2)/COVID-19 in Children
Connecticut Children's Medical Center
NCT04838834
COVID-19 in Patients With HIV
University of Missouri-Columbia
NCT04333953
Asymptomatic SARS-CoV-2 Detection in Children
University of Calgary
NCT04853316
Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers
Mayo Clinic
NCT04383587
SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding
University of Wisconsin, Madison
NCT04478019
A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants
ModernaTX
NCT04860297
Comparison of EPM-IX to Currently Used Specimen Transportation and Extraction Devices ( CGI-EPM-IX )
Convergent Genomics
NCT05281692
A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests
E25Bio
NCT04568356
Clinical Evaluation of a Point-of-Care (POC), COVID-19 Rapid Antigen Test (CoviDx™)
Lumos Diagnostics
NCT04750629
Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)
University of Minnesota
NCT04339998
NOWDx Test for the Detection of Antibodies to COVID-19
NOWDiagnostics
NCT04690413
Incidence of COVID-19 Test Conversion in Post-surgical Patients
Northwell Health
NCT04392323
Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
GlaxoSmithKline
NCT05260437
Rapid, Onsite COVID-19 Detection
University of Wisconsin, Madison
NCT04460690
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
Apellis Pharmaceuticals
NCT04402060
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult Participants
Generate Biomedicines
NCT07050511
A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.
Sean Liu
NCT05181709
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
University of Virginia
NCT04374565
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 4 |
| Phase 3 | 5 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on SARS-CoV-2 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on SARS-CoV-2 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this SARS-CoV-2 page
35 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 SARS-CoV-2 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- ModernaTX sponsors the most SARS-CoV-2 trials on record, review their full trial history before evaluating a specific study. See ModernaTX's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This SARS-CoV-2 condition card totals 35 registered trials; most-linked intervention mRNA-1273; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.